Ashwani Verma

how do you think that plays out? Like could this be a challenge if you have to titrate patients and some don't get the benefit of the efficacy

at this point, are you able to pursue first-line or naive patients in registrational studies

Just if you can share what are your expectations, here in these studies in terms of, the efficacy that would be great

Can you confirm the 1Q BRINSUPRI gross to net that you mentioned? Is it at the top end of the range, the mid-20s to low 30s?

do you have this data in-house already just realizing that the primary completion was also August

just trying to get a sense of how soon can we get there at the 4% run rate

is that the right way to think about how you spend it out as in thre's more potential for savings from commercial, followed by R&D and then COGS

I wanted to ask about the China business. It seems particularly strong this quarter. I know you called out some purchasing patterns. What's the growth excluding that

on the enterprise-wide strategic review, still waiting to hear a little bit of clarity in terms of what is the scope of activities that you want to showcase and what's the time line for that

can you help us understand how fast acting is this? For example, how quickly does this get static benefit in terms of hours

Is there more appetite here to go up substantially on the repo given where the stock is